PRESCRIBING CAUTION: From Wall Street, a Warning About Cancer-Drug Prices;
<h3>Morgan Stanley Analyst Creates Stir in Industry As He Sees a Backlash</h3><p class="source">The Wall Street Journal</p>
<p>In the spring of last year, a taxpayer group in California began publicly condemning Genentech for charging too much for Avastin, noting that the federal government's National Institutes of Health had subsidized some clinical trials of the drug. Not long after, Genentech said it was considering capping the price of Avastin.</p>
